Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...

Immunosuppressive medications. Drugs like corticosteroids or azathioprine work by calming the immune system and reducing the ...

Nanomedicine uses ultra-small particles to deliver drugs directly to the tissues and cells that need them, improving ...

UD researchers study how protein coatings influence nanoparticles' ability to avoid immune clearance and reach their ...

() -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.-based company's experimental drug, ...

Fred Ramsdell, 64, shared the award with two researchers for their discovery of how the human immune system knows not to ...

Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 ...

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.

Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...

The 2025 Nobel Prize in Physiology or Medicine honors three scientists who uncovered how the body maintains this crucial ...